Winter Springs, Florida, October 6, 2022 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent.

• Reports second quarter 2022 revenue of $12.7 million, GAAP diluted EPS of $0.26 and non-GAAP diluted EPS of $0.26

• Announces third quarter 2022 financial guidance

Winter Springs, Florida, July 22, 2022 – IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

Winter Springs, Florida, April 5, 2022 – IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 first quarter financial results before the market opens on Friday, April 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

Winter Springs, Florida, February 7, 2022 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Company’s outstanding common stock. This special cash dividend is payable on February 24, 2022 to shareholders of record at the close of business on February 17, 2022. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices. It produces the only known non-magnetic intravenous (“IV”) infusion pump system, and a non-magnetic patient vital signs monitoring system that is designed for use during MRI procedures.